George W. Lloyd - 06 Jul 2021 Form 4 Insider Report for Royalty Pharma plc (RPRX)

Signature
/s/ Sean Weisberg, as Attorney-in-Fact for George W. Lloyd
Issuer symbol
RPRX
Transactions as of
06 Jul 2021
Net transactions value
-$3,733,762
Form type
4
Filing time
08 Jul 2021, 19:36:12 UTC
Previous filing
14 Jun 2021
Next filing
14 Jul 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RPRX Class A Ordinary Shares Sale $264,119 -6,227 -1% $42.42 614,633 06 Jul 2021 By GWL 2013 NG, LLC F1
transaction RPRX Class A Ordinary Shares Sale $1,285,026 -30,303 -3.4% $42.41 849,697 06 Jul 2021 By GWL 2014 G, LLC F2
transaction RPRX Class A Ordinary Shares Sale $16,806 -400 -0.07% $42.02 614,233 07 Jul 2021 By GWL 2013 NG, LLC F3
transaction RPRX Class A Ordinary Shares Sale $105,022 -2,500 -0.29% $42.01 847,197 07 Jul 2021 By GWL 2014 G, LLC F4
transaction RPRX Class A Ordinary Shares Sale $352,888 -8,392 -1.4% $42.05 605,841 08 Jul 2021 By GWL 2013 NG, LLC F5
transaction RPRX Class A Ordinary Shares Sale $1,709,901 -40,667 -4.8% $42.05 806,530 08 Jul 2021 By GWL 2014 G, LLC F6
holding RPRX Class A Ordinary Shares 240,000 06 Jul 2021 By GWL 2020 G, LLC
holding RPRX Class A Ordinary Shares 3,000 06 Jul 2021 Direct
holding RPRX Class A Ordinary Shares 273,960 06 Jul 2021 By IRA
holding RPRX Class A Ordinary Shares 4,000 06 Jul 2021 By Spouse
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.04 to $42.88 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F2 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.84 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.01 to $42.02 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.03 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F6 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.00 to $42.21 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

All reported transactions were effected pursuant to 10b5-1 plans adopted by the reporting person on December 28, 2020. Exhibit List: Exhibit 24.1 - Power of Attorney